Drug Monitoring, Mitragynine, Quantitative, Urine
Also known as: Kratom, Pain Management, Prescription Drug Monitoring
Use
This test is intended to quantitatively measure mitragynine, the primary active alkaloid in kratom, in urine specimens. It is particularly useful in clinical and pain management settings where confirmation of kratom exposure and concentration monitoring is required, especially when preliminary screening has already been performed or when concentration data is necessary for interpretation. Quantitative results can support therapeutic monitoring, detect potential misuse, and inform clinical decisions regarding patient sedation or inconsistent opioid responses.
Special Instructions
Ordering this quantitative assay is appropriate when preliminary screening has already taken place or when concentration data is specifically required, as opposed to an immunoassay screen with reflex confirmation. For clinical support, Quest Diagnostics provides an Rx Tox Line that can assist with interpretation of this test.
Limitations
Routine immunoassay drug screens do not detect mitragynine; specialized methods such as LC‑MS/MS are required. Results may be influenced by hydration status, timing relative to ingestion, metabolic rate, and dosing of kratom. Quantitative values should be interpreted in clinical context, as concentration thresholds for impairment or therapeutic levels are not standardized.
Methodology
Mass Spectrometry
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
Not provided
Minimum Volume
Not provided